peptide garden
Peptide Profile

CagriSema

Cagrilintide + Semaglutide Fixed-Dose Combination

An investigational fixed-dose combination of cagrilintide and semaglutide from Novo Nordisk. It targets GLP-1 and amylin pathways and is under FDA review for weight management.

Reviewed October 1, 2026·12 min read·15 citations·NDA filedGLP-1 + amylin

At a glance

CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. It is technically a combination product, not a single peptide, but it belongs in the metabolic peptide evidence universe because it pairs GLP-1 biology with amylin biology in one once-weekly injection. It is not FDA-approved; Novo Nordisk filed the US NDA in December 2025 and, as of its August 2026 investor update, expects a US decision in the fourth quarter of 2026. That is company guidance, not a published FDA decision date.

Animal studiesModerateMechanistic support

The individual components have strong mechanistic rationale, but CagriSema itself is primarily supported by human clinical trials rather than a large independent animal literature.

Human evidenceStrong7,800+ participants

Two published Phase 3 REDEFINE obesity trials plus the three published Phase 3 REIMAGINE diabetes trials (REIMAGINE 1-3, presented at ADA 2026), with earlier Phase 1b and Phase 2 studies, show clinically meaningful weight and glycemic effects. FDA review for weight management is still pending and no diabetes indication is approved.

Safety dataModeratePhase 1-3 exposure

Safety is mostly gastrointestinal and broadly consistent with GLP-1/amylin pharmacology. Longer-term, post-marketing, and rare-event data are not available because the product is not approved.

How are these scores calculated?

CagriSema's strongest signal is simple: adding amylin agonism to semaglutide produced more weight loss than either component alone in REDEFINE 1. The caution is equally simple: NDA filing is not approval, and the full real-world safety picture does not exist yet.

New research, delivered clearly

When new studies publish or clinical trials report results, we'll break them down in plain language.

Quick facts

Components
Cagrilintide 2.4 mg + semaglutide 2.4 mg
Route
Once-weekly subcutaneous injection
Developer
Novo Nordisk
FDA status
Under FDA review; not approved
Main program
REDEFINE / REIMAGINE
Mechanism
GLP-1 receptor + amylin receptor pathways

Amino acid sequence

Fixed-dose combination product: cagrilintide + semaglutide


What is CagriSema?

CagriSema is a once-weekly injectable combination being developed by Novo Nordisk for weight management and type 2 diabetes. The two active components are semaglutide, the GLP-1 receptor agonist used in Wegovy and Ozempic, and cagrilintide, a long-acting amylin analogue.[5]

That makes CagriSema different from drugs such as tirzepatide or retatrutide. Tirzepatide and retatrutide are single molecules that hit multiple incretin receptors. CagriSema is a fixed-dose product combining two separate peptide drugs in one injection.

The reason it matters is the amylin pathway. GLP-1 drugs already reduce appetite, slow gastric emptying, and improve glucose handling. Amylin adds a complementary satiety signal, and REDEFINE 1 directly tested whether the combination outperformed each component alone.[1]

Regulatory status: CagriSema is under FDA review for weight management after a December 2025 NDA filing, and Novo has told investors it expects a US decision in the fourth quarter of 2026. It is not an approved prescription medicine yet. Any commercial sale before approval should be treated as unapproved.


How it works

CagriSema tries to cover two appetite-regulation channels at once:

  • Semaglutide: activates GLP-1 receptors, increasing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying, and reducing appetite.
  • Cagrilintide: mimics amylin, a pancreatic hormone co-secreted with insulin that promotes satiety and helps regulate post-meal glucagon.

In plain terms, CagriSema is built around the idea that GLP-1 and amylin send overlapping but not identical "stop eating" signals. The clinical question was whether the combination would do more than either signal alone. REDEFINE 1 supports that additive idea in adults without diabetes; REDEFINE 2 supports it in adults with type 2 diabetes and overweight or obesity.[1][2] The dedicated REIMAGINE diabetes program went further: in REIMAGINE 2, CagriSema beat both semaglutide and cagrilintide monotherapy on HbA1c and weight, which is the most direct test yet that adding amylin to GLP-1 helps in type 2 diabetes specifically.[7]

How CagriSema differs from amycretin

CagriSema and amycretin both sit in the GLP-1 + amylin trend, but they are not the same design.

  • CagriSema: two separate molecules, cagrilintide and semaglutide, co-formulated or co-administered as a fixed-dose treatment.
  • Amycretin / zenagamtide: one unimolecular drug designed to activate both GLP-1 and amylin receptor pathways.

This distinction matters for dosing, manufacturing, pharmacokinetics, and regulatory review. CagriSema is closer to market because it has completed pivotal Phase 3 obesity trials and has an FDA NDA filed. Amycretin has striking early data but still needs pivotal Phase 3 confirmation.


What the research says

CagriSema is the cleanest clinical proof so far that amylin agonism can add meaningful weight loss on top of GLP-1 therapy. With the REIMAGINE 1-3 diabetes trials now published, the type 2 diabetes evidence is strong too — but the product is still pre-approval and pre-real-world.

Peptide Garden evidence assessment, August 2026

Research timeline

  1. 2021Human study

    Phase 1b combination study

    Cagrilintide was co-administered with semaglutide 2.4 mg in a randomized Phase 1b study, establishing early safety, PK, and pharmacodynamic context.

  2. 2023Human study

    Phase 2 type 2 diabetes data

    A small active-controlled Phase 2 trial in T2D showed the combination produced greater weight and glycemic effects than either component alone.

  3. 2025Human study

    REDEFINE 1 and REDEFINE 2 published

    Two Phase 3a trials were published in the New England Journal of Medicine, establishing the pivotal obesity and T2D evidence base.

  4. 2025Regulatory

    FDA NDA filed

    Novo Nordisk submitted a US NDA for CagriSema for chronic weight management in December 2025. In August 2026 the company told investors it expects a US decision in the fourth quarter of 2026 — company guidance, not a published FDA action date.

  5. 2026Human study

    REIMAGINE 1-3 diabetes results published

    After a February 2026 topline announcement, the three Phase 3 REIMAGINE diabetes trials were presented as late-breaking data at ADA 2026 (New Orleans, June 7) and published in The Lancet and The Lancet Diabetes & Endocrinology. REIMAGINE 2 showed CagriSema superior to both semaglutide and cagrilintide monotherapy.

Key clinical trials

2025·Phase 3a, double-blind, randomized, placebo- and active-controlled·n=3417High quality

REDEFINE 1 — CagriSema for obesity without diabetes

Obesity or overweight with at least one comorbidity, without diabetes

At 68 weeks, CagriSema produced about 22.7% mean body-weight reduction under the trial-product estimand and was superior to semaglutide, cagrilintide, and placebo.

2025·Phase 3a, double-blind, randomized, placebo-controlled·n=1206High quality

REDEFINE 2 — CagriSema for overweight/obesity with type 2 diabetes

Type 2 diabetes with overweight or obesity

CagriSema produced clinically meaningful weight loss and glycemic improvement versus placebo over 68 weeks in a T2D population.

2026·Phase 3a, double-blind, randomized, placebo- and active-controlled·n=2713High quality

REIMAGINE 2 — CagriSema vs semaglutide and cagrilintide in T2D

Type 2 diabetes on metformin ± SGLT2 inhibitor

At 68 weeks, CagriSema 2.4/2.4 mg cut HbA1c by about 1.91 points and reduced weight by about 14.2%, superior to semaglutide 2.4 mg (about -1.75 points, -10.2%) and to cagrilintide. About a quarter of CagriSema participants lost at least 20% of body weight.

2026·Phase 3a, double-blind, randomized, placebo-controlled·n=189High quality

REIMAGINE 1 — CagriSema in drug-naive T2D

Type 2 diabetes inadequately controlled on diet and exercise

At 40 weeks, CagriSema reduced HbA1c by about 1.8 percentage points and body weight by about 13.8% versus placebo.

2026·Phase 3a, double-blind, randomized, placebo-controlled·n=274High quality

REIMAGINE 3 — CagriSema added to basal insulin

Type 2 diabetes on basal insulin

At 40 weeks, adding CagriSema to basal insulin reduced HbA1c by up to about 2.33 percentage points and body weight by about 12.0% versus placebo.

2023·Multicenter, randomized, double-blind, active-controlled·n=92Moderate quality

Phase 2 CagriSema in type 2 diabetes

Type 2 diabetes with overweight or obesity

The combination produced greater weight loss and glycemic improvement than either semaglutide or cagrilintide alone over 32 weeks.


What the evidence shows

Does CagriSema produce large weight loss?

Yes. REDEFINE 1 reported about 22.7% mean weight loss at 68 weeks under the trial-product estimand and showed superiority over semaglutide, cagrilintide, and placebo.

Well-supported

Is the amylin component meaningful?

Yes. Because REDEFINE 1 included both monotherapy arms, the trial directly supports that cagrilintide adds clinically meaningful weight loss on top of semaglutide.

Well-supported

Does CagriSema help type 2 diabetes?

Yes. The three published Phase 3 REIMAGINE trials (presented at ADA 2026) show large HbA1c and weight reductions across the T2D spectrum — drug-naive, on metformin, and on basal insulin — and in REIMAGINE 2 CagriSema was superior to both semaglutide and cagrilintide alone. It is not yet approved for diabetes.

Well-supported

Is CagriSema better than tirzepatide?

No. REDEFINE 4, an 84-week head-to-head Phase 3 in 809 adults with obesity, did not meet its primary endpoint of non-inferiority to tirzepatide 15 mg: 23.0% weight loss vs 25.5% (efficacy estimand) and 20.2% vs 23.6% (treatment-regimen estimand). The diabetes head-to-heads, REIMAGINE 4 and 5, are still ongoing with no results reported.

More research needed

Is CagriSema FDA-approved?

Not yet. The FDA NDA was filed in December 2025, and Novo said in August 2026 that it expects a US decision in the fourth quarter of 2026 — its own expectation, not a published FDA decision date. CagriSema remains investigational until the FDA acts, and a decision could be an approval, a rejection, or a request for more information.

Not yet demonstrated

A September 2026 meta-analysis pooled eight RCTs (6,898 participants), finding greater weight reduction than semaglutide, cagrilintide and placebo, with more gastrointestinal events. Weight comparisons had substantial heterogeneity, and these participants overlap earlier trial reports. The review does not establish cardiovascular-event benefit or reverse the separate REDEFINE-4 non-inferiority failure against tirzepatide.[15]

Safety & side effects

The main tolerability issue is gastrointestinal: nausea, vomiting, diarrhea, constipation, and appetite-related effects. That is expected from GLP-1 and amylin biology. REDEFINE 1 and REDEFINE 2 did not create a mature post-marketing safety dataset; they created a pre-approval trial dataset.[1][2]

Practical safety gaps:

  • No post-marketing pharmacovigilance.
  • No long-term real-world persistence data.
  • No completed cardiovascular outcomes trial specific to CagriSema.
  • Unknown rare-event profile in broader, less-selected populations.
  • Dose escalation and dose flexibility appear important for tolerability.

The safety question is not whether CagriSema has side effects. It does. The question is whether the additional weight loss from adding amylin is worth the added tolerability burden for a given patient population. That answer will depend on FDA labeling, payer coverage, and real-world use.


CagriSema is not FDA-approved as of this review. Novo Nordisk filed its US NDA for weight management on December 18, 2025.[5] The product remains investigational until FDA review is complete.

What "a Q4 2026 decision" does and doesn't mean

In its second-quarter 2026 investor presentation, published August 5, 2026, Novo Nordisk listed CagriSema under regulatory milestones as "US decision — Q4 2026," and said on its programme slide that it expects a US decision on the obesity submission in the fourth quarter of the year.[11]

That is worth reading precisely, because this is the kind of detail that gets flattened in coverage. It is Novo's own expectation, stated to investors. It is not a PDUFA date — the target action date the FDA sets for itself and, in many cases, discloses. Neither the FDA nor Novo has published such a date for CagriSema. So the honest summary is: the company expects an answer before the end of 2026, and an answer could be an approval, a rejection, or a request for more information.

The practical implication for readers is simply that this page may be out of date sooner than most. If CagriSema is approved, it becomes a prescription medicine dispensed through pharmacies — not something that becomes available from peptide sellers.

For sport, CagriSema should be treated conservatively. It is not listed by name on the WADA 2026 list, but non-approved pharmacological substances are prohibited under S0. Because CagriSema contains an investigational component, athletes should not treat it as permitted without formal anti-doping guidance.[12]


Comparisons

REDEFINE 4: the head-to-head against tirzepatide, and what it found

Most weight-loss drug comparisons you will read are cross-trial — different populations, different protocols, different eras — and are close to worthless. CagriSema is one of the few cases where the comparison was actually run.

REDEFINE 4 randomized 809 adults with obesity and at least one comorbidity to CagriSema 2.4/2.4 mg or tirzepatide 15 mg for 84 weeks, open-label. Novo Nordisk announced the topline result on February 23, 2026.

CagriSema 2.4/2.4 mg Tirzepatide 15 mg
Weight loss, efficacy estimand 23.0% 25.5%
Weight loss, treatment-regimen estimand 20.2% 23.6%

The trial did not meet its primary endpoint of non-inferiority to tirzepatide.[13]

Three things to hold at once here:

  • 23% weight loss is a lot. In absolute terms this is a highly effective drug, and it would be the most effective obesity medicine ever tested had tirzepatide not existed.
  • It lost anyway. The trial was designed to show CagriSema was at least as good, and it did not clear that bar — by roughly 2.5 to 3.4 percentage points depending on the estimand.
  • "Did not prove non-inferior" is not "tirzepatide is proven superior." REDEFINE 4 was not powered to test superiority in the other direction, and open-label design is a real limitation when expectation and adherence can move the result either way.

If you encounter CagriSema marketed as the next step beyond tirzepatide, this is the trial to ask about.

Profile Mechanism Regulatory status Evidence readout
Semaglutide GLP-1 receptor agonist FDA-approved Strongest approved GLP-1 evidence base
Tirzepatide GIP + GLP-1 agonist FDA-approved Approved high-efficacy dual incretin — outperformed CagriSema in REDEFINE 4
CagriSema Semaglutide + cagrilintide Under FDA review; not approved Phase 3 obesity and T2D evidence
Amycretin Single-molecule GLP-1 + amylin agonist Investigational Strong early oral and injectable signals
Retatrutide GIP + GLP-1 + glucagon agonist Investigational Phase 3 program ongoing

Where the head-to-head question stands. In obesity it has been answered, and the answer is not the one Novo wanted — see REDEFINE 4 above. In type 2 diabetes it is still open: REIMAGINE 4 (CagriSema versus tirzepatide 15 mg) and REIMAGINE 5 (versus tirzepatide 5 mg), each enrolling roughly 1,000 adults, are ongoing with no results reported. Any claim that CagriSema beats tirzepatide is currently contradicted in obesity and unproven in diabetes.



References

  1. [1]
    Garvey WT, Blüher M, Osorto Contreras CK, et al.. “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2025. 393(7):635-647 DOI PubMedRCT

    REDEFINE 1. Large Phase 3a trial in adults without diabetes; compared CagriSema with semaglutide, cagrilintide, and placebo.

  2. [2]
    Davies MJ, Bajaj HS, Broholm C, et al.. “Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.” N Engl J Med. 2025. 393(7):648-659 DOI PubMedRCT

    REDEFINE 2. Phase 3a trial in adults with T2D and overweight or obesity; placebo-controlled with lifestyle intervention.

  3. [3]
    Frias JP, Deenadayalan S, Erichsen L, et al.. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” Lancet. 2023. 402:720-730 DOI PubMedRCT

    Small Phase 2 trial (n=92) comparing the combination with each component in people with T2D.

  4. [4]
    Enebo LB, Berthelsen KK, Kankam M, et al.. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.” Lancet. 2021. 397(10286):1736-1748 DOI PubMedRCT

    Early combination safety and PK/PD trial. Short duration and small cohorts; useful for dose-escalation and tolerability context.

  5. [5]
    Novo Nordisk. “Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management.” 2025. LinkReview

    Company announcement of FDA NDA submission. Regulatory milestone, not an approval decision.

  6. [6]
    REIMAGINE 1 trial investigators. “Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.” Lancet Diabetes Endocrinol. 2026. DOIRCT

    REIMAGINE 1. 40-week Phase 3a trial in drug-naive adults with T2D; presented at ADA 2026 (New Orleans) and published in The Lancet Diabetes & Endocrinology.

  7. [7]
    REIMAGINE 2 trial investigators. “Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.” Lancet Diabetes Endocrinol. 2026. DOIRCT

    REIMAGINE 2. 68-week Phase 3 trial (2,713 analyzed of 2,728 randomized) in adults with T2D on metformin with or without an SGLT2 inhibitor; CagriSema superior to both semaglutide and cagrilintide monotherapy. Presented at ADA 2026.

  8. [8]
    REIMAGINE 3 trial investigators. “Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.” Lancet. 2026. DOIRCT

    REIMAGINE 3. 40-week Phase 3a trial in adults with T2D on basal insulin; presented at ADA 2026 and published in The Lancet.

  9. [9]
    Novo Nordisk. “Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026.” 2026. LinkReview

    Company release summarizing the REIMAGINE 1-3 late-breaking presentations at ADA 2026 (topline first announced February 2, 2026).

  10. [10]
    Novo Nordisk. “Novo Nordisk Annual Report 2025 — Innovation and therapeutic focus.” 2026. LinkReview

    Corporate annual report summarizing CagriSema, cagrilintide, and zenagamtide program status.

  11. [11]
    Novo Nordisk. “Investor presentation, Second quarter of 2026.” 2026. LinkReview

    Corporate investor presentation dated August 5, 2026. Lists CagriSema under regulatory milestones as 'US decision — Q4 2026' and places CagriSema (NN9838) in the submitted column of the pipeline table. This is the company's expectation, not an FDA-disclosed target action date.

  12. [12]
    World Anti-Doping Agency. “The 2026 Prohibited List.” 2026. LinkReview

    Used for S0 non-approved-substance regulatory context.

  13. [13]
    Novo Nordisk A/S. “CagriSema demonstrated 23% weight loss in the head-to-head REDEFINE 4 trial but did not meet the primary endpoint of non-inferiority versus tirzepatide.” Novo Nordisk company announcement. 2026. LinkRCT

    Company announcement dated February 23, 2026 reporting topline REDEFINE 4 results: 84 weeks, 809 participants, open-label, CagriSema 2.4/2.4 mg vs tirzepatide 15 mg. Primary endpoint of non-inferiority NOT met. This is sponsor-reported topline data, not a peer-reviewed publication — but it is the sponsor reporting against its own interest, which is the circumstance in which company data is most credible.

  14. [14]
    Khan BW, Agha SA, Qamar I, et al.. “Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.” Naunyn Schmiedebergs Arch Pharmacol. 2026. DOI PubMedSystematic review

    Seven RCTs, 8,069 participants, PRISMA and Cochrane methods with RoB 2 and GRADE. Reports CagriSema superior to semaglutide (MD -7.58 kg), cagrilintide (-9.24 kg), and placebo (-13.99 kg). Note that it pools placebo- and component-controlled trials only; it does not include the head-to-head REDEFINE 4 comparison against tirzepatide, so it cannot speak to how CagriSema ranks against the best available alternative.

  15. [15]
    Shao C, Lin H, Yu J, et al.. “Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.” Diabetes Metab Syndr Obes. 2026. DOI PubMedSystematic review

    Eight RCTs with 6,898 participants; overlapping existing trials, not new independent enrollment. Substantial heterogeneity (I² 82–99% for weight contrasts), more gastrointestinal events and no long-term cardiovascular endpoints. Does not overturn the REDEFINE-4 non-inferiority failure against tirzepatide.


Medical disclaimer

Peptide Garden is an educational resource, not a medical provider. This page is informational and does not constitute medical advice. CagriSema is investigational and not FDA-approved; do not use unapproved products sold as CagriSema outside regulated clinical care or clinical trials.